...
首页> 外文期刊>BMC Nephrology >Transplantation of a kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report
【24h】

Transplantation of a kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report

机译:用SLC22A12(URAT1)基因的杂合突变移植肾脏突变导致肾低度血症:案例报告

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND:Renal hypouricemia (RHUC) is a genetic disorder caused by mutations in the SLC22A12 gene, which encodes the major uric acid (UA) transporter, URAT1. The clinical course of related, living donor-derived RHUC in patients undergoing kidney transplantation is poorly understood. Here, we report a case of kidney transplantation from a living relative who had an SLC22A12 mutation. After the transplantation, the recipient's fractional excretion of UA (FEUA) decreased, and chimeric tubular epithelium was observed.CASE PRESENTATION:A 40-year-old man underwent kidney transplantation. His sister was the kidney donor. Three weeks after the transplantation, he had low serum-UA, 148.7?μmol/L, and elevated FEUA, 20.8% (normal: ?10%). The patient's sister had low serum-UA (101.1?μmol/L) and high FEUA (15.8%) before transplant. Suspecting RHUC, we performed next-generation sequencing on a gene panel containing RHUC-associated genes. A heterozygous missense mutation in the SLC22A12 gene was detected in the donor, but not in the recipient. The recipient's serum-UA level increased from 148.7?μmol/L to 231.9?μmol/L 3?months after transplantation and was 226.0?μmol/L 1?year after transplantation. His FEUA decreased from 20.8 to 11.7% 3?months after transplantation and was 12.4% 1?year after transplantation. Fluorescence in situ hybridization of allograft biopsies performed 3?months and 1?year after transplantation showed the presence of Y chromosomes in the tubular epithelial cells, suggesting the recipient's elevated serum-UA levels were owing to a chimeric tubular epithelium.CONCLUSIONS:We reported on a kidney transplant recipient that developed RHUC owing to his donor possessing a heterozygous mutation in the SLC22A12 (URAT1) gene. Despite this mutation, the clinical course was not problematic. Thus, the presence of donor-recipient chimerism in the tubular epithelium might positively affect the clinical course, at least in the short-term.
机译:背景:肾小血症(RHUC)是由SLC22A12基因突变引起的遗传疾病,其编码主要尿酸(UA)转运蛋白尿素1。接受肾移植的患者的相关临床过程,患有肾移植的患者较差。在这里,我们报告了来自具有SLC22A12突变的生活相对的肾移植的情况。移植后,接受者的UA(FeUA)的分数排泄减少,并且观察到嵌合管状上皮.Case介绍:一个40岁的男子接受了肾移植。他的妹妹是肾脏捐赠者。移植后三周,他的血清-UA低148.7?μmol/ L和升高的Feua,20.8%(正常:<?10%)。患者的姐姐在移植前血清UA(101.1μmol/ L)和高飞的FEUA(15.8%)。怀疑的Rhuc,我们在含有Rhuc-相关基因的基因面板上进行下一代测序。在供体中检测到SLC22A12基因中的杂合物畸变突变,但不在接受者中。受体的血清-UA水平从148.7?μmol/ l增加到231.9?μmol/ l 3?μmol/ l 3?μmol/ l 3?发生后的月份,移植后226.0?μmol/ l 1?他的Feua从20.8%降至11.7%3?移植后数月,移植后12.4%1?异种移植活组织检查的原位杂交的荧光在移植后进行3〜1〜1?在管状上皮细胞中存在Y染色体,表明受体升高的血清-UA水平由于嵌合管状上皮。结论:我们报道了由于他的供体在SLC22A12(URAT1)基因中具有杂合突变而发出RHUC的肾移植受体。尽管这种突变,临床过程并不有问题。因此,在管状上皮中的供体 - 受体逆变的存在可能会产生积极影响临床过程,至少在短期内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号